Adebrelimab Combined With Chemoradiotherapy in Patients With Large Bulky Stage III Unresectable Non-Small Cell Lung Cancer

Adebrelimab Combined With Chemoradiotherapy in Patients With Large Bulky Stage III Unresectable Non-Small Cell Lung Cancer is a phase 3, randomised interventional study registered as NCT07560358 by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, with a registry enrolment figure of 204 participants, started 2026-05-01 and due to reach its primary completion in 2029-12-31. Interventions recorded: After chemoimmunotherapy induction, followed by concurrent/sequential chemoradiotherapy and subsequent immune consolidation and maintenance therapy.; adebrelimab,Radiation Therapy,Radiotherapy. Conditions listed: NSCLC (Advanced Non-small Cell Lung Cancer). Primary outcome: Progression-Free Survival (PFS). Lung eligibility wording from the registry: "* Histologically or cytologically confirmed non-small cell lung cancer (NSCLC);". Sites: China. No results are recorded here; the registry entry is the source.